Table 1. Baseline patient cohort characteristics.
| siG12D LODERTM dose | ||||
|---|---|---|---|---|
| Parameter | 0.025 mg N=4 | 0.75 mg N=4 | 3 mg N=7 | All N=15 |
| Mean Age ± SD*, years | 65.8 ± 12.5 | 67.2 ± 6.0 | 71.5 ± 8.9 | 68.8 ± 9.0 |
| Median, years | 64.4 | 66.9 | 70.8 | 69.9 |
| (Range) | (52.1–82.0) | (60.9–74.2) | (57.6–85.3) | (52.1–85.3) |
| Gender: | ||||
| Male, N (%) | 3 (75.0) | 1 (25.0) | 4 (57.1) | 8 (53.3) |
| Female, N (%) | 1 (25.0) | 3 (75.0) | 3 (42.9) | 7 (46.7) |
| Smoker: | ||||
| Current (%) | 1 (25.0) | - | - | 1 (6.7) |
| Past (%) | 1 (25.0) | - | - | 1 (6.7) |
| Concomitant chemotherapy | ||||
| Treatment | siG12D LODERTM dose | |||
| 0.025 mg N=4 | 0.75 mg N=4 | 3 mg N=7 | All N=15** | |
| Gemcitabine | 2 | 4 | 3 | 9 |
| Oxaliplatin + Irinotecan +Fluorouracil | - | - | 4 | 4 |
| Gemcitabine + Erlotinib + Oxaliplatin | 1 | - | - | 1 |
| None | 1 | - | - | 1 |
*
SD=standard deviation
**
Number of patients enrolled (Two patients were omitted due to metastatic disease detected on day 1 post siG12D-LODERTM implantation)